Medtronic Neuromodulation – FDA 483, May 9, 2012

An FDA inspection of Medtronic Neuromodulation, a medical device manufacturer, was conducted from March 14 to May 9, 2012. The inspection revealed multiple significant deficiencies in the company's quality system, primarily related to corrective and preventive actions (CAPA), complaint handling, and regulatory reporting, falling under the FDA's medical device regulations. Key violations included the failure to adequately establish CAPA procedures, specifically regarding a long-standing issue of motor corrosion in SynchroMed II Pumps that had resulted in numerous device failures and remained unaddressed since 2007. The company also demonstrated severe shortcomings in its complaint handling process. This encompassed inadequate documentation of critical patient information from calls into written records, failure to transfer all event details to complaint files, and a pervasive lack of formal investigations for complaints involving device malfunctions like motor stalls and unexplained vibrations. Furthermore, Medtronic Neuromodulation exhibited inconsistent coding of similar complaints, hindering effective trend analysis, and failed to adequately trend complaint data due to incomplete information and system transition issues. These lapses led to delays in filing Medical Device Reports (MDRs) and Adverse Drug Experience (ADE) reports. The company also accepted supplier analyses for components without independently verifying their reliability. To address these observations, Medtronic Neuromodulation is required to implement comprehensive corrective actions, including revising and adhering to procedures for CAPA, complaint intake and investigation, data trending, and regulatory reporting, along with validating supplier data.